

## Answers to reviewers

Dear editor,

We want to thank you and the reviewers for their efforts. All requested modifications by the reviewers and in the manuscript were effectuated.

Reviewer 1:

Good review, no major comment. Authors can mention in one sentence that the dilemn of first line does not only consist to choose between FOFIRINOX and ABRAGEM, but also the fact that the eligible patients (PS 0-1,normal bilirubin level)are the same who could also be included in clinical trials to test new drugs/therapeutic strategies.

Answer: The requested modification was added .

Reviewer 2:

The manuscript by Marwan Ghosn and colleagues reviews first line treatment options for pancreatic cancer. The manuscript is -in general- well written and the included information is valid. Although both Folfirinox and Gemcitabine/Abraxane are nowadays standard in first line therapy, the described trials have been published several years ago. The comparison of both trials is not especially timely. Minor point: ABRAGEM is not a widely used abbreviation in the English literature.

Answer: As requested by the reviewer, ABRAGEM was replaced by Gemcitabine-Nab-Paclitaxel (GNP)